AstraZeneca, Thermo Fisher to develop develop solid tissue and blood-based companion diagnostic for Tagrisso

Imfinzi + chemo shows improved EFS and OS in muscle-invasive bladder cancer

Positive results from the NIAGARA phase III trial showed Imfinzi (durvalumab)in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival and the key secondary endpoint of overall survival versus neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer.

September 20, 2024

Vol.50 No.35

Clinical Roundup

Follow-up data for Imfinzi + Imjudo shows OS benefit in unresectable HCC

Updated results from the HIMALAYA phase III trial showed AstraZeneca’s Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) demonstrated a sustained, clinically meaningful overall survival benefit at five years for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy and were not eligible for localized treatment.

September 20, 2024

Vol.50 No.35

In Brief

Thermo Fisher opens Oncomine Clinical Research grant; announces latest awardees

Thermo Fisher Scientific announced the latest recipients of the Oncomine Clinical Research Grant, designed to support emerging research on molecular profiling in oncology and to help democratize the future of precision medicine.

September 13, 2024

Vol.50 No.34

Drugs & Targets

FDA grants Imfinzi priority review and Breakthrough Therapy designation for limited-stage SCLC

FDA granted priority review for Imfinzi (durvalumab), AstraZeneca’s supplemental Biologics License Application, based on the results from the positive ADRIATIC phase III trial in patients with limited-stage small cell lung cancer whose disease has not progressed following platinum-based concurrent chemoradiotherapy.

September 06, 2024

Vol.50 No.33

Clinical Roundup

Calquence combination significantly improved PFS in CLL in phase III trial

Positive high-level results from an interim analysis of the AMPLIFY phase III trial showed a fixed duration of Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukemia.

August 02, 2024

Vol.50 No.31

Clinical Roundup

Thermo Fisher, NCI collaborate to advance myeloid cancer research, treatment utilizing next-gen sequencing technology

To help accelerate research into new treatments for acute myeloid leukemia and myelodysplastic syndrome, Thermo Fisher Scientific Inc. is partnering with NCI on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial.

July 26, 2024

Vol.50 No.30

AstraZeneca, Thermo Fisher to develop develop solid tissue and blood-based companion diagnostic for Tagrisso

YOU MAY BE INTERESTED IN

Imfinzi + chemo shows improved EFS and OS in muscle-invasive bladder cancer

Follow-up data for Imfinzi + Imjudo shows OS benefit in unresectable HCC

Thermo Fisher opens Oncomine Clinical Research grant; announces latest awardees

FDA grants Imfinzi priority review and Breakthrough Therapy designation for limited-stage SCLC

Calquence combination significantly improved PFS in CLL in phase III trial

Thermo Fisher, NCI collaborate to advance myeloid cancer research, treatment utilizing next-gen sequencing technology

Renew today!

Subscriber content

Login